ANTI-SARS-CoV-2 MONOCLONAL ANTIBODIES
AssigneeWashington University
InventorsAli Ellebedy, Aaron Schmitz, Jackson Turner, Wafaa Al Soussi, Michael Diamond, Daved Fremont, James Brett Case, Haiyan Zhao, Adrianus Boon, Sean Whelan, Andrew McCluskey, Christopher Negron
Life of this patent
Estimating the term…
Abstract
The present invention relates to antibodies or antigen-binding fragments that are useful for treating coronavirus infections (e.g., COVID-19 caused by SARS-CoV-2). The present invention also relates to various pharmaceutical compositions and methods of treating coronavirus using the antibodies or antigen-binding fragments.
Claims31
An antibody comprising:
- an immunoglobulin heavy chain variable region comprising an amino acid sequence of SEQ ID NO:
- 27 and an immunoglobulin light chain variable region comprising an amino acid sequence of SEQ ID NO:
- 31, or
- an immunoglobulin heavy chain variable region comprising an amino acid sequence of SEQ ID NO:
- 28 and an immunoglobulin light chain variable region comprising an amino acid sequence of SEQ ID NO:
- 32.
An antibody or antigen-binding fragment thereof comprising:
- (a) an immunoglobulin heavy chain variable region comprising a CDRH1 having an amino acid sequence comprising any one of SEQ ID NO:
- 1-4, a CDRH2 having an amino acid sequence comprising any one of SEQ ID NOs:
- 5-8, a CDRH3 having an amino acid sequence comprising any one of SEQ ID NOs:
- 9-12, or a combination of any thereof;
- (b) an immunoglobulin light chain variable region comprising a CDRL1 having an amino acid sequence comprising any one of SEQ ID NOs:
- 13-16, a CDRL2 having an amino acid sequence comprising any one of SEQ ID NOs:
- 17-20, a CDRL3 having an amino acid sequence comprising any one of SEQ ID NOs:
- 21-24, or a combination of any thereof;
- or
- (c) a combination thereof.
-20. (canceled)
-42. (canceled)
-48. (canceled)
The antibody or antigen-binding fragment of claim 48, wherein the antibody or antigen-binding fragment comprises:
- an immunoglobulin heavy chain variable region comprising a CDRH1 having an amino acid sequence comprising SEQ ID NO:
- 2, a CDRH2 having an amino acid sequence comprising SEQ ID NO:
- 6, and a CDRH3 having an amino acid sequence comprising SEQ ID NO:
- 10;
- and
- an immunoglobulin light chain variable region comprising a CDRL1 having an amino acid sequence comprising SEQ ID NO:
- 14, a CDRL2 having an amino acid sequence comprising SEQ ID NO:
- 18, and a CDRL3 having an amino acid sequence comprising SEQ ID NO:
- 22.
The antibody or antigen-binding fragment of claim 48, wherein the antibody or antigen-binding fragment comprises:
- an immunoglobulin heavy chain variable region comprising a CDRH1 having an amino acid sequence comprising SEQ ID NO:
- 3, a CDRH2 having an amino acid sequence comprising SEQ ID NO:
- 7, and a CDRH3 having an amino acid sequence comprising SEQ ID NO:
- 11;
- and
- an immunoglobulin light chain variable region comprising a CDRL1 having an amino acid sequence comprising SEQ ID NO:
- 15, a CDRL2 having an amino acid sequence comprising SEQ ID NO:
- 19, and a CDRL3 having an amino acid sequence comprising SEQ ID NO:
- 23.
The antibody or antigen-binding fragment of claim 48, wherein the antibody or antigen-binding fragment comprises:
- an immunoglobulin heavy chain variable region comprising a CDRH1 having an amino acid sequence comprising SEQ ID NO:
- 4, a CDRH2 having an amino acid sequence comprising SEQ ID NO:
- 8, and a CDRH3 having an amino acid sequence comprising SEQ ID NO:
- 12;
- and
- an immunoglobulin light chain variable region comprising a CDRL1 having an amino acid sequence comprising SEQ ID NO:
- 16, a CDRL2 having an amino acid sequence comprising SEQ ID NO:
- 20, and a CDRL3 having an amino acid sequence comprising SEQ ID NO:
- 24.
(canceled)
(canceled)
-86. (canceled)
(canceled)
-100. (canceled)
-107. (canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.